"The voice for cancer physicians and their patients in Massachusetts."

  • Home
  • Resources
  • FDA Approvals
  • FDA GRANTED REGULAR APPROVAL TO PEMBROLIZUMAB (KEYTRUDA) FOR PATIENTS WITH LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA

FDA GRANTED REGULAR APPROVAL TO PEMBROLIZUMAB (KEYTRUDA) FOR PATIENTS WITH LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA

22 May 2017 1:19 PM | Nathan Strunk (Administrator)

The U.S. Food and Drug Administration granted regular approval to pembrolizumab (Keytruda) for patients with locally advanced or metastatic urothelial carcinoma who have disease progression during or following platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. Read the full press release.

Massachusetts Society of Clinical Oncologists (c) 860 Winter Street, Waltham, MA. 02451

Waltham, MA. 02451

P.O. Box 549154, Waltham, MA, 02451
t: 781.434.7329 | f: 781.464.4896 |email: nstrunk@mms.org
Powered by Wild Apricot Membership Software